|
Lilly, Amylin, Alkermes Diabetes Drug Gets EU Backing
Wall Street Journal NEW YORK (Dow Jones)–An injectable once-weekly diabetes drug, Bydureon, being developed by Eli Lilly & Co. (LLY), Amylin Pharmaceuticals Inc. (AMLN) and Alkermes Inc. (ALKS) obtained a key recommendation that … Lilly, Amylin diabetes drug wins EU recommendation Panel OKs diabetes drug Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug |
View full post on Health – Google News
